Sustained-release naltrexone may slightly increase illicit opioid use and serious adverse events compared to opioid agonists, with uncertain effects on retention and acceptability. It may reduce ...

Akums Drugs & Pharmaceuticals was recently granted a patent for its breakthrough 'tablet in tablet' technology --- designed ...

bupropion hydrochloride is also made as a twice-daily sustained-release tablet (bupropion SR), as well as a once-daily extended-release tablet (known as bupropion XL). Wellbutrin is sold as ...

GSK markets controlled sustained-release tablets of bupropion hydrochloride as Wellbutrin SR for the treatment of depression and as Zyban for smoking cessation. The cases began when Impax ...

Tablet’ Technology Brings relief for expectant mothers: Our Bureau, Bengaluru Monday, May 5, 2025, 13:45 Hrs [IST] Akums Drugs & Pharmaceuticals, a ...

Akums receives DCGI approval and a patent for its dual-action, extended-release Doxylamine-Pyridoxine formulation for ...

Objective: To compare the 24-hour sustained efficacy and safety ... of Contramid ® permits the design of tablets that are tailored to release tramadol continuously over a 24-hour period.

The controlled-release oxycodone tablet formulation (OCRT) was approved in China in 2004 for management of moderate to severe cancer pain. Few data about the efficacy of OCRT and clinical outcomes ...